Climb Bio Inc
Veridion Score
Composite trend over time
Why is CLYM moving today?
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CLYM.
CLYM insider activity
Climb Bio Inc
No multi-insider buying cluster in the last 90 days
Net buying: $19.9M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | 2026-04-29 | RA Capital Healthcare Fund LP | Insider | buy | $9.50 | 2,106,000 | 22,546,000 | $20.0M | SEC Form 4 |
| 2026-02-27 | 2026-02-26 | Thomas Stephen Basil | Insider | sell | $7.01 | 16,313 | 154,657 | $114K | SEC Form 4 |
| 2026-02-27 | 2026-02-25 | Thomas Stephen Basil | Insider | sell | $7.00 | 33,687 | 170,970 | $236K | SEC Form 4 |
| 2026-02-17 | 2026-02-13 | Thomas Stephen Basil | Insider | sell | $5.81 | 10,000 | 204,657 | $58K | SEC Form 4 |
| 2026-02-17 | 2026-02-12 | Thomas Stephen Basil | Insider | sell | $5.23 | 90,000 | 214,657 | $471K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 4 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moCLYM contract awards, year to date.
Public federal awards linked to this ticker.
CLYM lobbying filings, year to date.
Registered lobbying filings matched to Climb Bio Inc.